Get the newest information from the Immunization Program right in your inbox!
Sign up
Trouble logging in? Forgot password? We can help!
215-685-6784
215-238-6944
Complete the online reporting agreement form
Or fill out the
then email it to
vaxreporting@phila.gov
or fax to the contact above.
Complete in addition to the reporting agreement form to onboard more than 2 clinics.
Need help? Review the FAQ
If you or a colleague is not receiving our email advisories, follow the instructions below to ensure you receive future messages. Please forward this message to colleagues who may be facing issues with receiving our updates. 1. Check your junk or spam folders to ensure our...
Protect your patients against respiratory diseases by ordering free, educational print materials for your office! These materials are designed to facilitate informed conversations about immunizations and help tailor discussions to patients’ individual circumstances. Need support when discussing the importance and safety of vaccines? We also...
The Vaccines for Adults at Risk (VFAAR) program's FluLaval supply has run out for the season. Pediatric influenza vaccine doses are still available through the Vaccines for Children (VFC) program for VFC-eligible patients. Please do not submit any new orders for adult influenza vaccine, as these requests will be rejected. For...
The vaccine distribution center will have reduced delivery capacity during the holiday season. Orders submitted during this time will take longer than usual to ship. November: Place your order by Friday, November 14, 2025, at 12 p.m. Orders placed after this date may not ship until December...
On September 18-19, 2025, CDC's Advisory Committee on Immunization Practices (ACIP) voted to recommend: MMRV (combined MMR + varicella) vaccine should not be given to children under 4 years old. It is recommended to administer MMR and varicella vaccines separately. Clinical Background: MMRV Vaccine The MMRV vaccine is a...
VFC providers can now order Moderna, Pfizer, & Sanofi 2025-2026 COVID-19 products for their eligible patients.Make sure that your EHR/EMR is set-up to report this year’s COVID-19 products.These are the vaccines available this year: *Pfizer 6 mos - 4 years is no longer available.**This is a...
On February 14, 2025, the Food and Drug Administration (FDA) approved GSK’s MenABCWY vaccine, Penmenvy, for use in individuals aged 10 through 25 years. Penmenvy (meningococcal groups A, B, C, W, and Y vaccine) is now available through the Vaccines for Children (VFC) program. The vaccine is...
Vaccines for Children (VFC) providers are now welcome to order nirsevimab (Beyfortus) as needed. Nirsevimab (Beyfortus), a monoclonal antibody immunization used to prevent RSV infection in infants and young children, can be administered from October 1, 2025 to March 31, 2026. Once we receive your nirsevimab orders,...
The following products are now available to order: Flulaval (VFC & VFAAR) Fluzone (VFC only) Flucelvax (VFC only) FluMist (VFC only) 2025-2026 Available Influenza Products Vaccines for Children (VFC) Product Manufacture/NDC Eligibility Dose / Presentation / Type CPT Code CVX Code Available FluLaval GSK, 19515-0904-52 6 mos – 18 years 0.5 mL / Single-dose syringe / inactivated, trivalent 90656 140 Yes Fluzone Sanofi, 49281-0425-50 6 mos – 18...
Effective immediately, all 2024-2025 COVID-19 products are no longer approved for use. Remove all 2024-2025 COVID-19 vaccines from storage units immediately, even if they are not expired. Discard any open vials of vaccine and adjust inventory using the Wasting Vaccine Guide. Return any unopened vials or syringes using the Vaccine Return Guide. Mark...
The Philadelphia Immunization Program has free print materials available for your office to order. We recently sent a sample of these materials to your offices, so keep an eye out! Review the materials below and click the button at the bottom of this message to place...
As we prepare for the upcoming 2025-2026 season, our program would like to understand your practice's plans for offering COVID-19 vaccine to pediatric patients in light of recent CDC policy changes. Effective July 1, 2025, Vaccines for Children (VFC) providers are no longer required to order...
Beginning in September, the Philadelphia Immunization Program will be implementing a new ordering process for the Vaccines for Adults at Risk (VFAAR) program. All VFAAR orders should be submitted by the end of the day on the first Wednesday of each month. Orders will be reviewed...
FluLaval pre-filled syringes and Flucelvax pre-filled syringes are now available to order for your VFC-eligible patients. FluLaval pre-filled syringes are now available to order for your VFAAR-eligible patients. Visit our flu webpage to learn more about which vaccines are available and how to place your first order...
The Immunization Champion Award, hosted by the Association of Immunization Managers (AIM) and funded by the Centers for Disease Control and Prevention (CDC), recognizes individuals doing an exemplary job or going above and beyond to promote or foster immunizations in their communities for children and adults. The award...
2025-2026 VFC & VFAAR influenza products will be available to order soon. Make sure your office is ready! Starting Tuesday, August 12, 2025: FluLaval and Flucelvax will be available to order for your VFC-eligible patients. FluLaval will be available to order for your VFAAR-eligible patients. Complete a return in PhilaVax for any...
Join us for an informative virtual session on respiratory viruses. This session is for both primary care physicians (PCPs) and other vaccine providers to learn more about: respiratory syncytial virus (RSV) influenza COVID-19 vaccine ordering, storage, and administration information Infectious disease expert Dr. Mayssa Abuali will give an overview of...
Nirsevimab (Beyfortus) ordering will begin in August for the 2025-2026 season. Nirsevimab (Beyfortus), a monoclonal antibody immunization used to prevent RSV infection in infants and young children, can be administered from October 1, 2025, to March 31, 2026. The CDC plans to continue releasing nirsevimab (Beyfortus) through...